Suppr超能文献

左乙拉西坦的抗惊厥作用是否呈剂量依赖性?

Is the anticonvulsant activity of levetiracetam dose-dependent?

机构信息

Kork Epilepsy Center, Kehl-Kork, Germany; Department of Pediatrics, St-Elisabethen-Krankenhaus, Lörrach, Germany.

Kork Epilepsy Center, Kehl-Kork, Germany.

出版信息

Seizure. 2020 Dec;83:197-202. doi: 10.1016/j.seizure.2020.10.031. Epub 2020 Nov 4.

Abstract

PURPOSE

Although levetiracetam (LEV) is globally established as a leading antiseizure medication (ASM) it is still a controversial matter whether dose increases correspond with an increased efficacy if LEV in the recommended dose range did not show satisfying efficacy. In our clinical perception we questioned the value of dose increases in such non-responders.

METHODS

In this retrospective monocenter study we analyzed the data of adult people with epilepsies (PWE) with focal-onset seizures who had been treated at the department of adults of the Kork Epilepsy Center between 2009 and 2019, who had been on a stable daily LEV dose and in whom LEV was further increased due to further seizures in spite of baseline LEV in a recommended daily dose range. For reasons of data homogeneity, we included only PWE with at least two definite seizures during the hospital stay under the baseline LEV dose who were treated and observed as in-patients after the increase of LEV for a period at least three-fold longer than the baseline interval before. Additional data acquisition comprised clinical data including adverse events, serum concentrations of LEV and other ASMs, and additional laboratory findings. The primary outcome variable was the change of seizure frequency prior to and after the increase of LEV.

RESULTS

Out of 518 PWE who had been on LEV during their hospital stay, a total of 61 PWE fulfilled the inclusion criteria. After a gradual dose increment, 91,8 % of PWE showed a reduced seizure frequency, 73,8 % had a reduction of seizures of 50 % or more, and 21,3 % were seizure-free during the observation period. A significant seizure reduction could be shown with a seizure count of 2,5/week prior to the increment and 0,7/week after dose increment (p < 0,00001). Seven PWE reported minor adverse events and ten PWE showed slight laboratory changes (within normal levels).

CONCLUSION

Contrary to our long-term clinical impression, LEV dose increments were reasonable and improved the seizure situation in PWE, usually without additional safety hazards.

摘要

目的

虽然左乙拉西坦(LEV)已在全球范围内被确立为一种主要的抗癫痫药物(ASM),但在推荐剂量范围内,如果 LEV 没有显示出令人满意的疗效,增加剂量是否会相应提高疗效,这仍然是一个有争议的问题。根据我们的临床观察,我们对在这种无反应者中增加剂量的价值提出了质疑。

方法

在这项回顾性单中心研究中,我们分析了 2009 年至 2019 年间在 Kork 癫痫中心成人部门接受治疗的局灶性发作性癫痫患者(PWE)的数据,这些患者每日服用稳定剂量的 LEV,并且尽管基线 LEV 在推荐的每日剂量范围内,但由于进一步发作而进一步增加了 LEV 剂量。出于数据同质性的原因,我们仅纳入了在基线 LEV 剂量下住院期间至少有两次明确发作的 PWE,并且在 LEV 剂量增加后作为住院患者进行治疗和观察,观察期至少是基线间隔的三倍长。额外的数据采集包括临床数据,包括不良反应、LEV 和其他 ASM 的血清浓度以及其他实验室发现。主要结局变量是在增加 LEV 前后癫痫发作频率的变化。

结果

在住院期间接受 LEV 治疗的 518 名 PWE 中,共有 61 名 PWE 符合纳入标准。在逐渐增加剂量后,91.8%的 PWE 癫痫发作频率降低,73.8%的 PWE 癫痫发作减少 50%或更多,21.3%的 PWE 在观察期间无癫痫发作。在增加剂量前癫痫发作计数为 2.5/周,增加剂量后为 0.7/周,可显著减少癫痫发作(p<0.00001)。7 名 PWE 报告有轻微不良反应,10 名 PWE 显示轻微实验室变化(在正常范围内)。

结论

与我们长期的临床印象相反,增加 LEV 剂量是合理的,可以改善 PWE 的癫痫发作情况,通常不会增加额外的安全风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验